CHICAGO, IL – November 14, 2013 (PRNewswire) – Positron Corporation (OTCBB:POSC)(the “Company”), a nuclear medicine healthcare company, is pleased to announce the appointment of Joseph G. Oliverio as its President. Mr. Oliverio will direct the Company’s cardiac PET mission and oversee Positron’s PET technology, radiopharmaceutical partnerships, clinical and technical applications for new customer sales and existing users.
Joseph Oliverio has been a member of Positron’s Board of Directors since 2006 and has served as its President, Chief Technical Officer and Executive Director of PET during that time. Mr. Oliverio has been instrumental in guiding the development and introduction of Positron’s cardiac PET technology and has provided the vision of its molecular imaging strategy since joining the Company. Mr. Oliverio was a pioneer as Chief Operating Officer for the first freestanding heart disease reversal and prevention clinic guided by PET, and the first community based hospital offering cardiac PET in the emergency room setting, combined with an innovative heart disease reversal program. As a Certified Nuclear Medicine Technologist, Mr. Oliverio has performed over 13,000 cardiac studies on Positron imaging systems.
Oliverio commented, “I am excited to lead the company’s PET initiatives as President of Positron. We are aggressively pursuing a complete cardiac PET solution from radioisotopes, radiopharmaceuticals, imaging devices, clinical guidance and innovative financing structures. Positron is ideally positioned to take a leadership role in the nuclear cardiology industry. The caliber of the team and the Company’s history, coupled with its strong market positioning, makes this a tremendous opportunity.”
“Over the years, Joe Oliverio’s knowledge of the cardiac PET industry and history with the Company has been critical to the development of Positron’s technology and vertically integrated business plan,” said Patrick G. Rooney, CEO of Positron. “The demand for cardiac PET is stronger than ever and Joe’s expertise is ideally suited to execute Positron’s cardiac mission and to facilitate the growth of this modality.”
Positron Corporation is a nuclear medicine healthcare company vertically integrating all the segments of nuclear cardiology; providing an end-to-end solution for cardiac PET. Through proprietary PET imaging systems, radiopharmaceuticals and radioisotopes solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron’s unique products, market position and approach in securing the supply chain are substantial advantages, further accelerating the adoption of cardiac PET and growth of nuclear cardiology. Positron is redefining the industry. More information about Positron is available at http://www.positron.com.
Forward Looking Statements:
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission.
For more information, contact: